학술논문
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
Document Type
Article
Author
Partanen, A.; Waage, A.; Peceliunas, V.; Schjesvold, F.; Anttila, P.; Silvennoinen, R.; Säily, M.; Uttervall, K.; Putkonen, M.; Carlson, K.; Haukas, E.; Sankelo, M.; Szatkowski, D.; Hansson, M.; Marttila, A.; Svensson, R.; Axelsson, P.; Lauri, B.; Mikkola, M.; Karlsson, C.; Abelsson, J.; Ahlstrand, E.; Sikiö, A.; Klimkowska, M.; Matuzeviciene, R.; Fenstad, M.H.; Ilveskero, S.; Pelliniemi, T.-T.; Nahi, H.
Source
In: Cancers . (Cancers, March 2024, 16(5))
Subject
Language
English
ISSN
20726694